About Us
Motorpharma Ltd. is the most dynamically developing spin-off company established by Prof. András Málnási-Csizmadia for the development and exploitation of innovative ideas. The Málnási-laboratory at Eötöv Loránd University has been one of the flagships of actin-myosin motor protein research for the last two decades supported by international grants including Wellcome Trust, EMBO, Howard Hughes and ERC. MPH-220 , the leading drug candidate of Motorpharma Ltd. was successfully licensed to Motric Bio Inc. We are proud to have received an ERC PoC Grant, achieved by only 9 companies in the Central European region since the start of ERC PoC in 2011. The myosin inhibitors distributed by Motorpharma initiated a drug development project targeting myosin 2 isoforms to promote recovery after stroke.
Prof. András Málnási-Csizmadia, PhD, DSc
Founder, chairman
Máté Gyimesi, PhD
Chief Scientific Officer
Anna Rauscher, PhD
Chief Executive Officer
Balázs Jelinek, PhD
Founder and Chief Executive Officer
Our Mission
On one hand, at Motorpharma we want to make research easier by distributing improved inhibitors. On the other hand, we also want to take research to a next level by offering photoreactive inhibitors that enable localised treatment. Whether you want to simplify your protocols or go real high-tech, our team will help you achieve your goal.
